

Molecular Cancer Therapeutics

A Journal of the American Association for Cancer Research

Volume 4, Number 8

August 2005

Research Articles: Targets

- Murine double minute 2 as a therapeutic target for radiation sensitization of lung cancer**1137
Carolyn Cao, Eric T. Shinohara, Kenneth J. Niermann, Edwin F. Donnelly,
Xinping Chen, Dennis E. Hallahan, and Bo Lu
- Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer**1146
Maher N. Younes, Seungwon Kim, Orhan G. Yigitbasi, Mahitosh Mandal,
Samar A. Jasser, Yasemin Dakak Yazici, Bradley A. Schiff, Adel El-Naggar,
Benjamin N. Bekele, Gordon B. Mills, and Jeffrey N. Myers
- Competitive disruption of the tumor-promoting function of membrane type 1 matrix metalloproteinase/matrix metalloproteinase-14 *in vivo***1157
Takahiro Nonaka, Kunika Nishibashi, Yoshifumi Itoh, Ikuo Yana, and Motoharu Seiki
- T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study**1167
Sabrina Pricl, Maurizio Ferrmeglia, Marco Ferrone, and Elena Tamborini

Research Articles: Therapeutics

- Hedamycin, a DNA alkylator, induces γ H2AX and chromosome aberrations: Involvement of phosphatidylinositol 3-kinase-related kinases and DNA replication fork movement**1175
Lan Chun Tu, Sei ichi Matsui, and Terry A. Beerman
- Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930**1186
Filippo Petti, April Thelemann, Jen Kahler, Siobhan McCormack, Linda Castaldo,
Tony Hunt, Lydia Nuwaysir, Lynn Zeiske, Herbert Haack, Laura Sullivan,
Andrew Garton, and John D. Haley
- Validation of *in vivo* pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis**1198
Michael R. D'Andrea, Jay M. Mei, Robert W. Tuman, Robert A. Galemno,
and Dana L. Johnson
- The immunocytokine scFv23/TNF sensitizes HER-2/neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1**1205
Mi-Ae Lyu and Michael G. Rosenblum
- Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody**1214
Yan Wang, Judith Hailey, Denise Williams, Yaolin Wang, Philip Lipari, Michael Malkowski,
Xiaoying Wang, Lei Xie, Guanghua Li, Deba Saha, Wai Lam W. Ling, Susan Cannon-Carlson,
Robert Greenberg, Robert A. Ramos, Robert Shields, Leonard Presta, Peter Brams,
W. Robert Bishop, and Jonathan A. Pachter

contents continued

Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines1222
Pilar García-Morales, Angeles Gómez-Martínez, Alfredo Carrato, Isabel Martínez-Lacaci, Víctor M. Barberá, José L. Soto, Estefanía Carrasco-García, María P. Menéndez-Gutierrez, María D. Castro-Galache, José A. Ferragut, and Miguel Saceda

Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death1231
Ragnhild V. Nome, Åse Bratland, Gunhild Harman, Øystein Fodstad, Yvonne Andersson, and Anne Hansen Ree

Selenium disrupts estrogen receptor α signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells1239
Yatrik M. Shah, Mariam Al-Dhaheeri, Yan Dong, Clement Ip, Frank E. Jones, and Brian G. Rowan


Mitochondria are the primary target in isothiocyanate-induced apoptosis in human bladder cancer cells1250
Li Tang and Yuesheng Zhang

The antiproliferative agent MLN944 preferentially inhibits transcription1260
Sarah A. Byers, Blanca Schafer, Darshan S. Sappal, Jeffery Brown, and David H. Price

Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells1268
Lars Petter Jordheim, Olivier Guittet, Michel Lepoivre, Carlos M. Galmarini, and Charles Dumontet

Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria1277
Chin-Chung Wu, Mei-Ling Chan, Wen-Ying Chen, Ching-Yi Tsai, Fang-Rong Chang, and Yang-Chang Wu

Information for Authors i



On the Cover

Immunofluorescence TUNEL (*green*) and CD31 (*red*) staining for apoptotic and endothelial cells, respectively, from anaplastic thyroid cancer xenografts. DRO tumors were treated with the new integrin-linked kinase (ILK) inhibitor KP74728 at 50mg/kg/day (*upper panel*) and 100mg/kg/day (*lower panel*) dose. KP74728 induced apoptosis and reduced angiogenesis at the lower dose. However, at the higher dose, there was a significant increase in apoptosis of tumor-associated endothelial cells as marked by the overlay of apoptotic cells (*green*) on tumor blood vessels (*red*). For details, see Younes et al. in this issue.